LUMO Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $1.37 and $4.58. With a market capitalization of about $37.54 million, Lumos Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 102.98 thousand shares, trading with heavier-than-usual volume. Headquartered in Austin, TX, Lumos Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard J. Hawkins, the company employs approximately 30 people and listed since November 11, 2011. Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases.

Lumos Pharma, Inc. generated EPS of -$4.28 over the past year. Five-year average earnings growth is 20.27%. Wall Street analysts project EPS growth of 15.2% annually over the next five years. The latest quarter delivered EPS of -$0.90. The next quarter is forecast at -$0.52. Next year's EPS is expected at $19.27. Lumos Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2024, missed forecasts by 18.42%. The prior quarter beat by -26.19%. Over the last six quarters, Apple has recorded several small beats. These include 1.74% in February 14, 2024.

Lumos Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

Short-term trend indicators are bearishly aligned (SMA20 0.34%, SMA50 3.61%, SMA200 40.73%). The stock’s 14-day RSI is 55.58 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.15% below its high and over 216.77% above its low.

Lumos Pharma, Inc. has 8.65 million shares outstanding. The public float is 5.66 million shares, elevated short interest at 0.87% of float. This equals 54.33 thousand shares. The short ratio is 0.59 days. Institutional investors hold 36.06% of the float. Insiders own 32.69%. Stine Seed Farm, Inc. holds 7.86 million shares, Flynn James E has 784.57 thousand shares and LALANDE KEVIN M. has 730.45 thousand shares.

Lumos Pharma, Inc. (NASDAQ:LUMO) shares are up 36.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lumos Pharma, Inc. trading at a premium to the broader market with a P/E of -2.41. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $20.43, suggesting 370.74% upside. Our AI forecast model points to short-term strength (0.23% over two weeks), a medium-term fall (-6.91% over three months), and a longer-term gain (475.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lumos Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.23%, with price expected at $4.35 by December 27, 2024, within a range of $4.32 to $4.38 3-Month Outlook: Projected fall of -6.91%, reaching $4.04 by March 11, 2025, with a range of $3.82 to $4.29. 1-Year Outlook: Projected gain of 475.81%, with price at $24.99 by December 11, 2025, within a range of $24.61 to $31.13.

Lumos Pharma, Inc. trades at a P/E ratio of -2.41, slightly below the S&P 500 average, with a price-to-sales ratio of 30.92 and a price-to-book ratio of 7.35 trading at moderately above to book value. The P/FCF stands at -3.3, also below market averages.